STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more

The investment arm of Novo Nordisk’s parent foundation is buying Catalent, a contract development and manufacturing company with more than 50 sites globally.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks